scholarly journals Hepatic Arterial Embolization versus Chemoembolization in the Treatment of Liver Metastases from Well-Differentiated Midgut Endocrine Tumors: A Prospective Randomized Study

2012 ◽  
Vol 96 (4) ◽  
pp. 294-300 ◽  
Author(s):  
Frédérique Maire ◽  
Catherine Lombard-Bohas ◽  
Dermot O’Toole ◽  
Marie-Pierre Vullierme ◽  
Vinciane Rebours ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Randomized Study ◽  
Arterial Embolization ◽  
Prospective Randomized Study ◽  
Endocrine Tumors ◽  
Well Differentiated ◽  
Hepatic Arterial Embolization

Successful Control of Liver Metastases From Pancreatic Solid-Pseudopapillary Neoplasm (SPN) Using Hepatic Arterial Embolization

2014 ◽  
Vol 38 (2) ◽  
pp. 479-483 ◽  
Author(s):  
Elena G. Violari ◽  
Lynn A. Brody ◽  
Anne M. Covey ◽  
Joseph P. Erinjeri ◽  
George I. Getrajdman ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Arterial Embolization ◽  
Solid Pseudopapillary Neoplasm ◽  
Successful Control ◽  
Hepatic Arterial Embolization

scholarly journals Hepatic Arterial Embolization for the Treatment of Metastatic Neuroendocrine Tumors

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Eric Lee ◽  
H. Leon Pachter ◽  
Umut Sarpel
Keyword(s):  
Liver Metastases ◽  
Neuroendocrine Tumors ◽  
Survival Rates ◽  
Arterial Embolization ◽  
Progression Free Survival ◽  
Term Survival ◽  
Free Survival ◽  
Hepatic Arterial Embolization

Neuroendocrine tumors (NETs) have a high predilection for metastasizing to the liver and can cause severe debilitating symptoms adversely affecting quality of life. Although surgery remains the treatment of choice, many liver metastases are inoperable at presentation. Hepatic arterial embolization procedures take advantage of the arterial supply of NET metastases. The goals of these therapies are twofold: to increase overall survival by stabilizing tumor growth, and to reduce the morbidity in symptomatic patients. Patients treated with hepatic arterial embolization demonstrate longer progression-free survival and have 5-year survival rates of nearly 30%. The safety of repeat embolizations has also been proven in the setting of recurrent symptoms or progression of the disease. Despite not being curative, hepatic arterial embolization should be used in the management of NETs with liver metastases. Long-term survival is not uncommon, making aggressive palliation of symptoms an important component of treatment.

Hepatic Arterial Embolization and Chemoembolization in the Management of Patients with Large-Volume Liver Metastases

2007 ◽  
Vol 31 (2) ◽  
pp. 299-307 ◽  
Author(s):  
Paresh P. Kamat ◽  
Sanjay Gupta ◽  
Joe E. Ensor ◽  
Ravi Murthy ◽  
Kamran Ahrar ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Large Volume ◽  
Arterial Embolization ◽  
Hepatic Arterial Embolization

scholarly journals Hepatic Arterial Embolization Versus Chemoembolization in Patients With Liver Metastases of a Digestive Neuroendocrine Tumors

2011 ◽  
Vol 140 (5) ◽  
pp. S-875
Author(s):  
Frédérique Maire ◽  
Catherine Lombard-Bohas ◽  
Dermot O'Toole ◽  
Marie-Pierre Vullierme ◽  
Vinciane Rebours ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Neuroendocrine Tumors ◽  
Arterial Embolization ◽  
Hepatic Arterial Embolization

Carcinoid Tumors of the Gut

1997 ◽  
Vol 4 (1) ◽  
pp. 18-24 ◽  
Author(s):  
John F. Sweeney ◽  
Alexander S. Rosemurgy
Keyword(s):  
Carcinoid Syndrome ◽  
Hepatic Metastases ◽  
Arterial Embolization ◽  
Primary Treatment ◽  
Carcinoid Tumors ◽  
Endocrine Tumors ◽  
Bioactive Substances ◽  
Surgical Debulking ◽  
Long Acting ◽  
Hepatic Arterial Embolization

Background Carcinoid tumors are the most frequently encountered endocrine tumors of the gastrointestinal tract. They are most often found in the appendix, although they can arise in any location of the gut. Carcinoid tumors may secrete a variety of bioactive substances, which can cause the complex of symptoms associated with the carcinoid syndrome. Methods The authors reviewed the pathology, clinical presentation, and management of carcinoid tumors with an emphasis on the surgical management. Results The primary treatment for a carcinoid tumor located anywhere in the gut is surgical. Those who have widely metastatic disease or who are anatomically unresectable may undergo cytoreductive surgical debulking and/or hepatic arterial embolization followed by palliation of symptoms with octreotide, the long-acting somatostatin analog. Conclusions The prognosis for patients with carcinoid tumors that are fully resected is excellent. Those with hepatic metastases and the carcinoid syndrome.

scholarly journals GEP-NETS UPDATE: Interventional radiology: role in the treatment of liver metastases from GEP-NETs

2015 ◽  
Vol 172 (4) ◽  
pp. R151-R166 ◽  
Author(s):  
Thierry de Baere ◽  
Frederic Deschamps ◽  
Lambros Tselikas ◽  
Michel Ducreux ◽  
David Planchard ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Randomized Study ◽  
Objective Response ◽  
Arterial Embolization ◽  
Tumor Burden ◽  
First Line Therapy ◽  
Large Size ◽  
Dominant Disease ◽  
Pancreatic Origin ◽  
Arterial Chemoembolization

Neuroendocrine tumors from gastro-pancreatic origin (GEP-NET) can be responsible for liver metastases. Such metastases can be the dominant part of the disease as well due to the tumor burden itself or the symptoms related to such liver metastases. Intra-arterial therapies are commonly used in liver only or liver-dominant disease and encompass trans-arterial chemoembolization (TACE), trans-arterial embolization (TAE), and radioembolization (RE). TACE performed with drug emulsified in Lipiodol has been used for the past 20 years with reported overall survival in the range of 3–4 years, with objective response up to 75%. Response to TACE is higher when treatment is used as a first-line therapy and degree of liver involvement is lower. Benefit of TACE over TAE is unproven in randomized study, but reported in retrospective studies namely in pancreatic NETs. RE provides early interesting results that need to be further evaluated in terms of benefit and toxicity. Radiofrequency ablation allows control of small size and numbered liver metastases, with low invasiveness. Ideal metastases to target are one metastasis <5 cm, or three metastases <3 cm, or a sum of diameter of all metastases below 8 cm. Ablation therapies can be applied in the lung or in the bones when needed, and more invasive surgery should be probably saved for large-size metastases. Even if the indication of image-guided therapy in the treatment of GEP-NET liver metastases needs to be refined, such therapies allow for manageable invasive set of treatments able to address oligometastatic patients in liver, lung, and bones. These treatments applied locally will save the benefit and the toxicity of systemic therapy for more advanced stage of the disease.

1374: A Two Years Follow-Up, Prospective Randomized Study on Cystocele Repair with or without Pelvicol Implant

2007 ◽  
Vol 177 (4S) ◽  
pp. 453-453 ◽  
Author(s):  
Ervin Kocjancic ◽  
Simone Crivellaro ◽  
Fabio Bernasconi ◽  
Fabio Magatti ◽  
Bruno Frea ◽  
...  
Keyword(s):  
Randomized Study ◽  
Prospective Randomized Study
Sign in / Sign up

Export Citation Format

Share Document